Answers are grounded in this paper and cite their sources.
Purpose Novel synthetic opioids (NSOs) are among the most dangerous new psychoactive substances due to their high risk of overdose and respiratory depression. Since 2019, a group of NSOs known as “orphines” has emerged on the European market. Spirochlorphine (R-6890), first detected in 2024, is a structurally distinct NSO containing a spirotriazole core rather than the more common benzimidazole core. This study reports in vitro µ- opioid receptor potency, discusses the first fatal intoxication involving this compound and compares it to other NSOs. Methods The in vitro potency of spirochlorphine at the µ -opioid receptor (MOR) was assessed using a G-protein based receptor activation assay. Spirochlorphine concentrations in postmortem samples were determined using LC-MS/MS via a standard addition approach to compensate matrix effects. Urine samples were analyzed using external matrix calibration. Results In vitro, spirochlorphine demonstrated higher MOR potency than fentanyl, with a lower EC 50 of 8.3 nM compared to 12.2 nM. In the postmortem samples spirochlorphine was detected at 9.5 ng/mL in femoral blood, 64 ng/g in liver, 95 ng/g in kidney, and 57 µg (absolute) in stomach contents. Co-detections in femoral blood included desalkylflurazepam (250 ng/mL) and rilmazolam (25 ng/mL). Hair analysis revealed chronic exposure to benzodiazepines and opioids. Conclusion Spirochlorphine proved to be at least equally as potent as fentanyl. Hence, in the investigated case involving spirochlorphine, rilmazolam, and desalkylflurazepam with indicated benzodiazepine tolerance, death was mainly attributed to spirochlorphine. Accordingly a toxicological significance score (TSS) of 3 was assigned to spirochlorphine.
No takes yet. Share an insight, caveat, or question.
Wrbas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: